Daria Lemann-Blumenthal CEOMrs. Lemnn-Blumenthal completed her LL.B. at the Hebrew University in Jerusalem and her Executive MBA at Tel-Aviv University, both degrees Dean`s Honors. She was CEO of Ein Tal Eye Center for 6 years.
Prof. Michael Belkin Founder & Medical DirectorProf. Belkin was awarded a masterís degree in science by Cambridge University, England, and received a doctorate in medicine from the Hebrew University of Jerusalem. He is a professor emeritus of ophthalmology and the director of the Ophthalmic Technologies Laboratory at the universityís Eye Research Institute in the Sheba Medical Center.
Dr. Modi Goldenfeld Medical AdvisorDr. Goldenfeld is a glaucoma specialist at the Sam Rothberg Glaucoma Center, Goldschleger Eye Institute, Sheba Medical Center. He received his MD degree from the Tel Aviv University and senior glaucoma specialist from Northwestern University, Chicago. Dr. Goldenfeld has also served as the Israeli Glaucoma Society chairman.
For more Information please visit:
Pilot Clinical Study
System Engineering & Testing
PrototypeDesign and Production
BELKIN Laser is developing a laser treatment for glaucoma that can be performed in one second. Glaucoma is the second leading cause of blindness in the world, affecting 60 million patients.
BELKIN Laser is developing a one-second glaucoma laser treatment, which will revolutionize access to glaucoma care. It is a simple, painless, non-invasive procedure. BELKIN Laser significantly reduces the skill required for performing the procedure, which is suitable for most glaucoma patients and is as effective as current treatments. Due to its simplicity and low-cost, BELKIN Laser has the potential of becoming first line treatment. Furthermore, BELKIN Laser offers a great promise to patients in East Assia, since the proposed technology easily conforms to their typical eye anatomy.
- Glaucoma is the second leading cause of blindness in the world, according to the World Health Organization.
- It is estimated that over 2.2 million Americans have glaucoma, and 17 million people in China.
- Glaucoma costs the US economy $2.86 billion every year.